Deerfield Management Company, L.P. (Series C) Akero Therapeutics, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2024 Aug 14, 2024	SELL	$18.31 - $24.62 $32,555 - $43,774	-1,778 Reduced 13.03%	11,867 $278,000
Q1 2024 May 15, 2024	BUY	$17.76 - $31.18 $242,335 - $425,451	13,645 New	13,645 $344,000

Others Institutions Holding AKRO

# of Institutions

190

Shares Held

73.8M

Call Options Held

241K

Put Options Held

647K

Wellington Management Group LLP Boston, MA

7.9M
Shares

$246 Million
0.04% of portfolio
Janus Henderson Group PLC London, X0

7.08M
Shares

$221 Million
0.11% of portfolio
Rtw Investments, LP New York, NY

5.92M
Shares

$184 Million
2.71% of portfolio
Black Rock Inc. New York, NY

5.59M
Shares

$174 Million
0.0% of portfolio
General Atlantic LLC New York, NY

5.23M
Shares

$163 Million
4.29% of portfolio

View Full List

About Akero Therapeutics, Inc.

Ticker AKRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,417,600
Market Cap $1.45B
Description
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...

More about AKRO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account